Vicore Pharma AB (VCRE) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vogenx is the larger company by market cap ($259.8 million vs $248.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VCRE | VOGX |
|---|---|---|
| Share price | $8.82 | $17.49 |
| Market cap | $248.41M | $259.82M |
| 1-day change | +1.85% | +8.23% |
| EPS (TTM) | $-2.04 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.80 | $38.41 |
| 52-week low | $7.88 | $12.95 |
| Distance from 52-week high | -50.45% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +275.96% | +214.47% |
| Average volume | 16.22K | 187.66K |
| Shares outstanding | 28.16M | 14.86M |
| Employees | 46 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
VCRE vs VOGX FAQ
Which is bigger, Vicore Pharma AB or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.82M compared with $248.41M for Vicore Pharma AB (VCRE).
Are Vicore Pharma AB and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.